These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
499 related articles for article (PubMed ID: 9014827)
1. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Fleischer J; Soeth E; Reiling N; Grage-Griebenow E; Flad HD; Ernst M Immunology; 1996 Dec; 89(4):592-8. PubMed ID: 9014827 [TBL] [Abstract][Full Text] [Related]
2. Decreased inducible expression of CD80 and CD86 in human monocytes after ultraviolet-B irradiation: its involvement in inactivation of allogenecity. Fujihara M; Takahashi TA; Azuma M; Ogiso C; Maekawa TL; Yagita H; Okumura K; Sekiguchi S Blood; 1996 Mar; 87(6):2386-93. PubMed ID: 8630402 [TBL] [Abstract][Full Text] [Related]
3. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. Denton MD; Geehan CS; Alexander SI; Sayegh MH; Briscoe DM J Exp Med; 1999 Aug; 190(4):555-66. PubMed ID: 10449526 [TBL] [Abstract][Full Text] [Related]
4. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189 [TBL] [Abstract][Full Text] [Related]
5. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules and dendritic cells on the immune response in leprosy. Santos DO; Santos SL; Esquenazi D; Nery JA; Defruyt M; Lorré K; Van Heuverswyn H Nihon Hansenbyo Gakkai Zasshi; 2001 Feb; 70(1):15-24. PubMed ID: 11244783 [TBL] [Abstract][Full Text] [Related]
7. Expression and function of the costimulatory molecules B7-1 (CD80) and B7-2 (CD86) in an in vitro model of the human blood--brain barrier. Omari KI; Dorovini-Zis K J Neuroimmunol; 2001 Feb; 113(1):129-141. PubMed ID: 11137584 [TBL] [Abstract][Full Text] [Related]
8. Costimulatory molecules in Wegener's granulomatosis (WG): lack of expression of CD28 and preferential up-regulation of its ligands B7-1 (CD80) and B7-2 (CD86) on T cells. Moosig F; Csernok E; Wang G; Gross WL Clin Exp Immunol; 1998 Oct; 114(1):113-8. PubMed ID: 9764612 [TBL] [Abstract][Full Text] [Related]
9. Differential function of CD80- and CD86-transfected human melanoma cells in the presence of IL-12 and IFN-gamma. Rudy W; Gückel B; Siebels M; Lindauer M; Meuer SC; Moebius U Int Immunol; 1997 Jun; 9(6):853-60. PubMed ID: 9199968 [TBL] [Abstract][Full Text] [Related]
10. Glucocorticoids inhibit activation-dependent expression of costimulatory molecule B7-1 in human monocytes. Girndt M; Sester U; Kaul H; Hünger F; Köhler H Transplantation; 1998 Aug; 66(3):370-5. PubMed ID: 9721807 [TBL] [Abstract][Full Text] [Related]
11. Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. Mitra RS; Judge TA; Nestle FO; Turka LA; Nickoloff BJ J Immunol; 1995 Mar; 154(6):2668-77. PubMed ID: 7533180 [TBL] [Abstract][Full Text] [Related]
12. FcR cross-linking on monocytes results in impaired T cell stimulatory capacity. Barcy S; Wettendorff M; Leo O; Urbain J; Kruger M; Ceuppens JL; de Boer M Int Immunol; 1995 Feb; 7(2):179-89. PubMed ID: 7537534 [TBL] [Abstract][Full Text] [Related]
13. Preferential expression of B7.2 (CD86), but not B7.1 (CD80), on B cells induced by CD40/CD40L interaction is essential for anti-DNA autoantibody production in patients with systemic lupus erythematosus. Nagafuchi H; Shimoyama Y; Kashiwakura J; Takeno M; Sakane T; Suzuki N Clin Exp Rheumatol; 2003; 21(1):71-7. PubMed ID: 12673892 [TBL] [Abstract][Full Text] [Related]
14. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro. Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504 [TBL] [Abstract][Full Text] [Related]
15. T-cell alterations in cardiac allograft recipients after B7 (CD80 and CD86) blockade. Woodward JE; Bayer AL; Chavin KD; Blue ML; Baliga P Transplantation; 1998 Jul; 66(1):14-20. PubMed ID: 9679816 [TBL] [Abstract][Full Text] [Related]
16. Mitogenic stimulation of T cells reveals differing contributions for B7-1 (CD80) and B7-2 (CD86) costimulation. Perrin PJ; Davis TA; Smoot DS; Abe R; June CH; Lee KP Immunology; 1997 Apr; 90(4):534-42. PubMed ID: 9176106 [TBL] [Abstract][Full Text] [Related]
17. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule. McLellan AD; Starling GC; Williams LA; Hock BD; Hart DN Eur J Immunol; 1995 Jul; 25(7):2064-8. PubMed ID: 7542604 [TBL] [Abstract][Full Text] [Related]
18. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Vandenborre K; Van Gool SW; Kasran A; Ceuppens JL; Boogaerts MA; Vandenberghe P Immunology; 1999 Nov; 98(3):413-21. PubMed ID: 10583602 [TBL] [Abstract][Full Text] [Related]
19. Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity. Vermeiren J; Ceuppens JL; Haegel-Kronenberger H; De Boer M; Boon L; Van Gool SW Clin Exp Immunol; 2004 Feb; 135(2):253-8. PubMed ID: 14738453 [TBL] [Abstract][Full Text] [Related]
20. Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Luque I; Reyburn H; Strominger JL Hum Immunol; 2000 Aug; 61(8):721-8. PubMed ID: 10980383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]